Management of Lung Cancer Screening Results Based on Individual Prediction of Current and Future Lung Cancer Risks [0.03%]
基于当前和未来肺癌风险预测的肺癌筛查结果管理
Hilary A Robbins,Li C Cheung,Anil K Chaturvedi et al.
Hilary A Robbins et al.
Objectives: We propose a risk-tailored approach for management of lung cancer screening results. This approach incorporates individual risk factors and low-dose computed tomography (LDCT) image features into calculations ...
Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors [0.03%]
由BRAFG469V突变驱动的肺癌可被EGFR激酶抑制剂攻击
Ku-Geng Huo,Hirotsugu Notsuda,Zhenhao Fang et al.
Ku-Geng Huo et al.
Introduction: Mutations in BRAF occur in 2% to 4% of patients with lung adenocarcinoma. Combination dabrafenib and trametinib, or single-agent vemurafenib is approved only for patients with cancers driven by the V600E BRA...
Tumor and Tumor-Associated Macrophage Programmed Death-Ligand 1 Expression Is Associated With Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma [0.03%]
肿瘤及其相关的巨噬细胞程序性死亡配体1的表达与肺腺癌辅助化疗的效果相关
Daniel J Gross,Navin K Chintala,Raj G Vaghjiani et al.
Daniel J Gross et al.
Introduction: Patients with stage II to III lung adenocarcinomas are treated with adjuvant chemotherapy (ACT) to target the premetastatic niche that persists after curative-intent resection. We hypothesized that the preme...
Prognostic Impact of the Histologic Lepidic Component in Pathologic Stage IA Adenocarcinoma [0.03%]
病理分期IA腺癌中组织学类皮脂腺成分的预后影响
Yu Okubo,Jumpei Kashima,Takashi Teishikata et al.
Yu Okubo et al.
Introduction: Because several articles have reported a prognostic association with the radiologic features of ground-glass opacity, we explored whether the histologic presence of a lepidic component had similar significan...
Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations [0.03%]
携带种系BAP1突变的恶性胸膜间皮瘤患者的脑膜瘤
Zishuo I Hu,Markku Miettinen,Martha Quezado et al.
Zishuo I Hu et al.
BAP1 is a tumor suppressor gene implicated in DNA repair and cell growth. Individuals with germline BAP1 mutations are at a significantly increased risk for developing many different cancers including malignant mesothelioma, uveal melanomas...
Deep RNA Sequencing Revealed Fusion Junctional Heterogeneity May Predict Crizotinib Treatment Efficacy in ALK-Rearranged NSCLC [0.03%]
深度RNA测序显示融合连接的异质性可能预测ALK重排NSCLC中克唑替尼治疗疗效
Zhengbo Song,Shifeng Lian,Silvia Mak et al.
Zhengbo Song et al.
Introduction: Gene fusion variants in ALK-rearranged NSCLC may predict patient outcomes, but previous results have been inconclusive. Fusion isoforms coexisting in the same tumor may affect the efficacy of targeted therap...
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain [0.03%]
阿特珠单抗联合贝伐珠单抗及化疗在具有EGFR突变或肝转移或脑转移的NSCLC患者关键亚组中的IMpower150最终探索性分析
Naoyuki Nogami,Fabrice Barlesi,Mark A Socinski et al.
Naoyuki Nogami et al.
Introduction: Final overall survival (OS) analyses are presented for EGFR mutations and liver or brain metastases subgroups in the phase 3 IMpower150 study (NCT02366143) evaluating atezolizumab plus bevacizumab plus carbo...
Patient Adherence to Lung CT Screening Reporting & Data System-Recommended Screening Intervals in the United States: A Systematic Review and Meta-Analysis [0.03%]
在美国患者对肺CT筛查报告及数据系统推荐筛查间隔的依从性：系统综述和荟萃分析
Yannan Lin,Mingzhou Fu,Ruiwen Ding et al.
Yannan Lin et al.
Lung cancer screening (LCS) is effective in reducing mortality, particularly when patients adhere to follow-up recommendations standardized by the Lung CT Screening Reporting & Data System (Lung-RADS). Nevertheless, patient adherence to rec...
Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC [0.03%]
TP53和KEAP1突变的综合分析及其对局部期和晚期NSCLC生存率的影响
Mohamed Mahde Saleh,Matthias Scheffler,Sabine Merkelbach-Bruse et al.
Mohamed Mahde Saleh et al.
Introduction: TP53 and KEAP1 are frequently mutated in NSCLC, but their prognostic value is ambiguous, particularly in localized stage tumors. Methods: ...
Scott P Myrand
Scott P Myrand